Combination chemotherapy of early and advanced murine P388 leukaemia with bouvardin, cis-diamminedichloroplatinum and vincristine.
A comparative study of cytostatic combinations was carried out in early and advanced murine leukaemia P388 by using the new protein synthesis inhibitor bouvardin (BVD) along with the known anticancer drugs vincristine (VCR) and cis-diamminedichloroplatinum (DDP). The results indicate that the combination of BVD with DDP enhances the antineoplastic activity in comparison with single-agent therapy in early leukaemia. However, BVD could not indicate its superiority by way of tumour cell killing in three drug combinations, when administered with VCR and/or DDP, against advanced leukaemia.
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D010456:Peptides, Cyclic / Q000627:therapeutic use; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D010456:Peptides, Cyclic; C018234:bouvardin; D014750:Vincristine; D002945:Cisplatin